⌘K

News & Disclosures/JCR Pharmaceuticals Co., Ltd. [4552]: Notice of the designation of givinostat, a treatment for Duchenne muscular dystrophy, as an orphan drug by the Ministry of Health, Labour and Welfare — 28 September 2026 (timely disclosure): Nikkei Company Information DIGITALHomeNews & DisclosuresJCR Pharmaceuticals Co., Ltd. [4552]: Notice of the designation of givinostat, a treatment for Duchenne muscular dystrophy, as an orphan drug by the Ministry of Health, Labour and Welfare — 28 September 2026 (timely disclosure): Nikkei Company Information DIGITAL

News4552JCR Pharmaceuticals Co.,Ltd.· Nikkei · 2026/10/22 16:35

JCR Pharmaceuticals Co., Ltd. [4552]: Notice of the designation of givinostat, a treatment for Duchenne muscular dystrophy, as an orphan drug by the Ministry of Health, Labour and Welfare — 28 September 2026 (timely disclosure): Nikkei Company Information DIGITAL

The Ministry of Health, Labour and Welfare has formally notified the orphan drug designation of givinostat, a treatment for Duchenne muscular dystrophy, submitted by JCR Pharmaceuticals Co., Ltd.

Read in fullFrom the source, not the headline

sources corroborateOutlets reporting the same event

companies linkedAcross 0 themes, second pass

The story

JCR Pharmaceuticals Co., Ltd. reports that givinostat has been designated by the Ministry of Health, Labour and Welfare as a treatment for Duchenne muscular dystrophy.

The notification was issued at 10:00 on 28 September 2026. The announcement materials are reportedly available on Nikkei Company Information DIGITAL.

At a glance

ClassificationMHLW announces orphan drug designation

Date and time28 September 2026 10:00

CompanyJCR Pharmaceuticals Co., Ltd.

Target diseaseDuchenne muscular dystrophy

Druggivinostat

Reference information. Every claim resolves to something the story actually named.

Where this came from

We read each source in full and checked they agree on the core claim.

1/ 1 agree

All of them report the same thing.

NikkeiNews

AgreesOpen

Read the original articleGo to the source page

Reference information generated from public sources. It does not solicit or advise on investments. Prices are 15-minute delayed.

JCR Pharmaceuticals Co., Ltd. [4552]: Notice of the designation of givinostat, a treatment for Duchenne muscular dystrophy, as an orphan drug by the Ministry of Health, Labour and Welfare — 28 September 2026 (timely disclosure): Nikkei Company Information DIGITAL | News